Baidu
map

JBC:邬振国教授解析横纹肌肉瘤抑癌miRNA

2013-11-28 佚名 睿医资讯

来自深圳北京大学香港科技大学医学中心、香港科技大学的研究人员证实,在横纹肌肉瘤中miR-203常常下调,其再表达可以抑制横纹肌肉瘤的生长和转移,促进其终末分化,表明miR-203是横纹肌肉瘤一个有潜力的治疗靶点。相关论文发表在11月18日的《生物化学杂志》(JBC)上。 【原文下载】 文章的通讯作者是任职于深圳北京大学香港科技大学医学中心和香港科技大学的邬振

来自深圳北京大学香港科技大学医学中心、香港科技大学的研究人员证实,在横纹肌肉瘤中miR-203常常下调,其再表达可以抑制横纹肌肉瘤的生长和转移,促进其终末分化,表明miR-203是横纹肌肉瘤一个有潜力的治疗靶点。相关论文发表在11月18日的《生物化学杂志》(JBC)上。 【原文下载】

文章的通讯作者是任职于深圳北京大学香港科技大学医学中心和香港科技大学的邬振国(Zhenguo Wu)教授。其主要研究方向包括:骨骼肌干细胞的调控及骨骼肌细胞分化的机理;EBV编码的LMP1的信号传导机理及鼻咽癌细胞中microRNA的研究。

横纹肌肉瘤(Rhabdomyosarcoma,RMS)是一组具有骨骼肌发生特征的异质性软组织恶性肿瘤,约占15岁以下儿童软组织肉瘤的50%,占儿童所有恶性肿瘤的4-8%。根据其组织学和遗传学特点可分为较常见的胚胎性横纹肌肉瘤(ERMS)、更具侵袭性的腺泡状横纹肌肉瘤(ARMS)和罕见的成人多形性横纹肌肉瘤(PRMS)。RMS在组织学、年龄、发病部位和预后上有着很大的差异,部分肿瘤形态学上分化很差,常常很难与一些小圆细胞肿瘤鉴别。因此,研究横纹肌肉瘤发生过程中的分子改变有助于阐明横纹肌肉瘤的发生机制,并对其诊断、治疗和预后评估具有重要意义。

多年来,已鉴别出许多促进肿瘤形成的蛋白质编码抑癌基因和癌基因。在过去的10年里,microRNA(miRNA)作为一种新型的非编码RNA出现,被证实参与调控了肿瘤形成。有研究显示,参与肿瘤形成的部分miRNAs可能是作为癌基因或是抑癌基因来发挥作用。此外,miRNA还能够通过调控其靶基因与其余相关基因之间的相互作用来参与大部分肿瘤的发生和发展。

当前,已有几个miRNAs被确定促进了横纹肌肉瘤形成。一组肌肉特异性miRNAs(MyomiR)包括miR-1、miR-133和miR-206被发现在横纹肌肉瘤中调控失常。此外,miR-26a、miR-29和miR-183也被证实在横纹肌肉瘤中失调控。miR-203是一种与许多癌症相关的miRNA,然而目前对于其在横纹肌肉瘤中的状态并不清楚。

在这篇文章中,研究人员在两种横纹肌肉瘤细胞系中证实通过启动子超甲基化导致了miR-203表达下调,采用DNA去甲基化制剂可以重激活miR-203。在横纹肌肉瘤细胞中重表达miR-203可以抑制其迁移和增殖,促进终末成肌分化。机制研究结果表明,在横纹肌肉瘤细胞中miR-203是通过直接靶向p63和白血病抑制因子受体(LIFR) 来发挥肿瘤抑制效应,并通过分别抑制Notch和JAK1/STAT1/STAT3信号通路促进了成肌分化。

这些研究结果表明,miR-203在横纹肌肉瘤形成中发挥了肿瘤抑制作用,其是是横纹肌肉瘤一个有潜力的治疗靶点。

原文出处:

Diao Y, Guo X, Jiang L, Wang G, Zhang C, Wan J, Jin Y, Wu Z.miR-203,a tumor suppressor frequently down-regulated by promoter hypermethylation in Rhabdomyosarcoma.J Biol Chem.2013 Nov 18. 【原文下载】

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1930386, encodeId=6860193038670, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Thu Apr 17 20:28:00 CST 2014, time=2014-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036400, encodeId=f3e32036400f6, content=<a href='/topic/show?id=0c901025932' target=_blank style='color:#2F92EE;'>#JBC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10259, encryptionId=0c901025932, topicName=JBC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Sun Jan 12 05:28:00 CST 2014, time=2014-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672714, encodeId=bd0f16e27149e, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Tue Feb 18 07:28:00 CST 2014, time=2014-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1640630, encodeId=e1be164063019, content=<a href='/topic/show?id=fd575494e5e' target=_blank style='color:#2F92EE;'>#抑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54947, encryptionId=fd575494e5e, topicName=抑癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f822706827, createdName=jingyanzhu715_39486108, createdTime=Sat Apr 26 20:28:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312257, encodeId=4fc5131225e7a, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Sat Nov 30 05:28:00 CST 2013, time=2013-11-30, status=1, ipAttribution=)]
    2014-04-17 smallant2002
  2. [GetPortalCommentsPageByObjectIdResponse(id=1930386, encodeId=6860193038670, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Thu Apr 17 20:28:00 CST 2014, time=2014-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036400, encodeId=f3e32036400f6, content=<a href='/topic/show?id=0c901025932' target=_blank style='color:#2F92EE;'>#JBC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10259, encryptionId=0c901025932, topicName=JBC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Sun Jan 12 05:28:00 CST 2014, time=2014-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672714, encodeId=bd0f16e27149e, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Tue Feb 18 07:28:00 CST 2014, time=2014-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1640630, encodeId=e1be164063019, content=<a href='/topic/show?id=fd575494e5e' target=_blank style='color:#2F92EE;'>#抑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54947, encryptionId=fd575494e5e, topicName=抑癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f822706827, createdName=jingyanzhu715_39486108, createdTime=Sat Apr 26 20:28:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312257, encodeId=4fc5131225e7a, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Sat Nov 30 05:28:00 CST 2013, time=2013-11-30, status=1, ipAttribution=)]
    2014-01-12 lily1616
  3. [GetPortalCommentsPageByObjectIdResponse(id=1930386, encodeId=6860193038670, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Thu Apr 17 20:28:00 CST 2014, time=2014-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036400, encodeId=f3e32036400f6, content=<a href='/topic/show?id=0c901025932' target=_blank style='color:#2F92EE;'>#JBC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10259, encryptionId=0c901025932, topicName=JBC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Sun Jan 12 05:28:00 CST 2014, time=2014-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672714, encodeId=bd0f16e27149e, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Tue Feb 18 07:28:00 CST 2014, time=2014-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1640630, encodeId=e1be164063019, content=<a href='/topic/show?id=fd575494e5e' target=_blank style='color:#2F92EE;'>#抑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54947, encryptionId=fd575494e5e, topicName=抑癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f822706827, createdName=jingyanzhu715_39486108, createdTime=Sat Apr 26 20:28:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312257, encodeId=4fc5131225e7a, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Sat Nov 30 05:28:00 CST 2013, time=2013-11-30, status=1, ipAttribution=)]
    2014-02-18 hongbochen
  4. [GetPortalCommentsPageByObjectIdResponse(id=1930386, encodeId=6860193038670, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Thu Apr 17 20:28:00 CST 2014, time=2014-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036400, encodeId=f3e32036400f6, content=<a href='/topic/show?id=0c901025932' target=_blank style='color:#2F92EE;'>#JBC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10259, encryptionId=0c901025932, topicName=JBC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Sun Jan 12 05:28:00 CST 2014, time=2014-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672714, encodeId=bd0f16e27149e, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Tue Feb 18 07:28:00 CST 2014, time=2014-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1640630, encodeId=e1be164063019, content=<a href='/topic/show?id=fd575494e5e' target=_blank style='color:#2F92EE;'>#抑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54947, encryptionId=fd575494e5e, topicName=抑癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f822706827, createdName=jingyanzhu715_39486108, createdTime=Sat Apr 26 20:28:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312257, encodeId=4fc5131225e7a, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Sat Nov 30 05:28:00 CST 2013, time=2013-11-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1930386, encodeId=6860193038670, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Thu Apr 17 20:28:00 CST 2014, time=2014-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036400, encodeId=f3e32036400f6, content=<a href='/topic/show?id=0c901025932' target=_blank style='color:#2F92EE;'>#JBC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10259, encryptionId=0c901025932, topicName=JBC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Sun Jan 12 05:28:00 CST 2014, time=2014-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1672714, encodeId=bd0f16e27149e, content=<a href='/topic/show?id=b79b910345c' target=_blank style='color:#2F92EE;'>#解析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91034, encryptionId=b79b910345c, topicName=解析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f42d26916490, createdName=hongbochen, createdTime=Tue Feb 18 07:28:00 CST 2014, time=2014-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1640630, encodeId=e1be164063019, content=<a href='/topic/show?id=fd575494e5e' target=_blank style='color:#2F92EE;'>#抑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54947, encryptionId=fd575494e5e, topicName=抑癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f822706827, createdName=jingyanzhu715_39486108, createdTime=Sat Apr 26 20:28:00 CST 2014, time=2014-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312257, encodeId=4fc5131225e7a, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Sat Nov 30 05:28:00 CST 2013, time=2013-11-30, status=1, ipAttribution=)]
    2013-11-30 Homburg

相关资讯

J Infect Dis:血浆病毒miRNA或可作为慢性活动型EB病毒感染分子标志

慢性活动型EB病毒感染(CAEBV)的临床特点类似于慢性或重复的感染性单核细胞增多症,如发热、淋巴结肿大等。CAEBV具有很高的发病率和死亡率,并伴随多种危及生命的并发症。造血干细胞移植已成为有效的治疗方法。血样本中的EB病毒DNA含量已被用于诊断疾病和评估疗效,但是,还没有发现能反映疾病严重程度、病程以及预后的其他生物标志物。miRNA属于小分子非编码RNA,与信使RNA的序列互补。已有研究表明

AJHG:有益脂肪或许能靶向miRNA降低心脏病风险

美国塔夫茨大学美国农业部人类营养老化研究中心(HNRCA)的科学家们已经发现了一个调节甘油三酸酯水平的新基因机制.这一途径可以保护一个基因变异的携带者对抗心血管疾病,特别是那些对多不饱和脂肪(PUFA)有更大摄入量的基因变异携带者.这一发现发表在 American Journal of Human Genetics杂志上,研究结果有助于开展能够改善公众健康和补充慢性疾病预防和治疗的基因特异的饮食策

NAT COMMUN :miR-17-5p可能是大肠癌进展关键调控因子

  近日来自上海同济大学附属第十人民医院和第六人民医院的研究人员在新研究中揭示了大肠癌进程的一个关键调控因子miR-17-5p及其分子机制,相关论文发表在12月18日的《自然通讯》(Nature Communications)杂志上。上海同济大学附属第十人民医院的秦环龙(Huanlong Qin)教授和马延磊(Yanlei Ma)博士为这篇论文的共同通讯作者。秦环龙教授主要从事胃肠道疾病的外科基础

缺乏两种小核糖核酸会导致不孕

当代社会不孕症发病率有明显上升趋势,而无法顺利排卵是导致不孕症的重要原因之一。日本一个研究小组在动物实验中发现,如果缺乏两种特定的小核糖核酸(miRNA),会引发排卵障碍。 小核糖核酸是一类不编码制造蛋白质的单链核糖核酸分子,主要参与控制基因表达,调节各种基因的功能。研究小组在实验中发现,如果雌性实验鼠体内缺乏miR―200b和miR―429这两种小核糖核酸,就难以怀孕。 研究小组检查体内缺乏

JBC:中国医学科学院解析抑癌miRNA

来自中国医学科学院的研究人员在新研究中证实,miRNA-200b通过影响Pin1的表达控制了失巢凋亡(anoikis),且miRNA-200b的表达受到两个ETS家族成员PEA3和ELK-1的调控。这些研究发现在线发表在9月26日的《生物化学杂志》(JBC)上   【原文下载】 论文的通讯作者是中国医学科学院北京协和医学院的刘志华(Zhihua Liu)博士。其回国前曾在美国

Genome Biol:乳腺癌中DNA甲基化和拷贝数改变调控miRNA异常表达

   挪威奥斯陆大学等机构的研究人员对乳腺癌队列人群进行分析,揭示了DNA甲基化和拷贝数改变对microRNA表达的影响,从而为乳腺癌中miRNA失调背后的机制提供了新证据。这项研究成果于11月20日发表在Genome Biology上。   microRNA(miRNA)是一类小的非编码RNA分子,它通过控制mRNA稳定性和翻译而在转录后水平上调控基因表达。之前的研究

Baidu
map
Baidu
map
Baidu
map